Phexxi Access to Expand under New Government Guidance Stating Insurers Must Cover FDA-approved Contraceptives with No Out-of-Pocket Costs to Women
Retrieved on:
Wednesday, January 12, 2022
Securities Exchange Act of 1934, Forward-looking statement, Patient, Reproductive health, SAN, Private Securities Litigation Reform Act, Ministry of Labour, SEC, Sex, HRSA, NASDAQ, Affordable Care Act, New York State Department of Labor, CEO, Lactic acid, Citric acid, Chlamydia, Department, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Care Act 2014, ACA, Gonorrhea, Company, Method, PBM, Food and Drug Administration, Food, Health Resources and Services Administration, Annual report, FDA, Compliance, Sexual Health Resource Centre, U.S. Department of Labor, Office of Inspector General, Woman, Birth control, Pharmaceutical industry, Labour
"We anticipate that millions more women will be able to access Phexxi at no cost without overly burdensome denials or being forced to try other products first."
Key Points:
- "We anticipate that millions more women will be able to access Phexxi at no cost without overly burdensome denials or being forced to try other products first."
- The Company's first FDA-approved product, Phexxi (lactic acid, citric acid and potassium bitartrate), is ahormone-free, on-demand prescription contraceptive vaginal gel.
- Forward-looking statements are statements other than historical facts and relate to future events or circumstances and the Company's future performance.
- The Company does not undertake any duty to update any forward-looking statement except as required by law.